Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2011
04/13/2011CN1882547B 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
04/13/2011CN1874774B Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
04/13/2011CN1842318B Use of biotin or a biotin derivative for lightening skin and treating age spots
04/13/2011CN1813711B Use of isoflavone compound
04/13/2011CN1780635B Preventives or remedies for hepatopathy
04/13/2011CN1780562B Food containing glycine and use thereof
04/13/2011CN1768873B Apparatus and method for electroporation mediated delivery for drugs and genes
04/13/2011CN1723019B Compounds having anti-proliferative properties
04/13/2011CN1665488B Direct cellular energy delivery system
04/13/2011CN1625400B 2,4-pyrimidinediamine compounds and their uses
04/13/2011CN102016054A Method for preparing ortho-dihydroxyisoflavones using a biotransformation system
04/13/2011CN102016036A Modified RNAi polynucleotides and uses thereof
04/13/2011CN102015750A 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use
04/13/2011CN102015743A Ruthenium compounds and compositions
04/13/2011CN102015739A Novel compounds and methods for therapy
04/13/2011CN102015728A Thiazolyl-dihydro-indazoles
04/13/2011CN102015727A Inhibitors of serine proteases
04/13/2011CN102015724A Thienopyrimidines
04/13/2011CN102015723A Inhibitors of protein tyrosine kinase activity
04/13/2011CN102015722A Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
04/13/2011CN102015720A Selective ligands for the neuronal nicotinic receptors and uses thereof
04/13/2011CN102015719A Pyrrolotriazine kinase inhibitors
04/13/2011CN102015718A 1- (7-(hexahydropyrrolo [3, 4-C] pyrrol-2 (1H) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)
04/13/2011CN102015716A Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease
04/13/2011CN102015715A Fused pyrimidineone compounds as TRPV3 modulators
04/13/2011CN102015714A 1' -substituted CARBA-nucleoside analogs for antiviral treatment
04/13/2011CN102015713A Inhibitors of protein kinases
04/13/2011CN102015712A Heterocyclic compounds as adenosine receptor antagonist
04/13/2011CN102015711A Spiro-indole derivatives for the treatment of parasitic diseases
04/13/2011CN102015710A Azatricyclic antibiotic compounds
04/13/2011CN102015709A Heterocyclic antiviral compounds
04/13/2011CN102015708A Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
04/13/2011CN102015707A RAF inhibitor compounds and methods of use thereof
04/13/2011CN102015706A Imidazolidinone derivatives as 11B-HSD1 inhibitors
04/13/2011CN102015705A Fused heterocyclic derivative and use thereof
04/13/2011CN102015702A Cyclic ethers
04/13/2011CN102015701A PIM kinase inhibitors and methods of their use
04/13/2011CN102015700A Antibacterial condensed thiazoles
04/13/2011CN102015699A Heterocyclic urea derivatives and methods of use thereof-211
04/13/2011CN102015698A Oxazolidinone derivatives
04/13/2011CN102015697A Amide derivative and pharmaceutical composition containing the same
04/13/2011CN102015696A Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
04/13/2011CN102015695A Pyridin-2-yl derivatives as immunomodulating agents
04/13/2011CN102015694A Pyridazinone derivatives
04/13/2011CN102015693A Compounds that are ERK inhibitors
04/13/2011CN102015692A Heterocyclic derivatives as hepatitis c virus inhibitors
04/13/2011CN102015691A Imidazo-pyridine derivatives as activin-like receptor kinase (ALK4 or ALK5) inhibitors
04/13/2011CN102015689A Inhibitors of JNK
04/13/2011CN102015688A Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof
04/13/2011CN102015687A Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
04/13/2011CN102015686A Novel heterocyclic compounds and uses therof
04/13/2011CN102015685A Substituted dihydropyrazolones as inhibitors of HIF-prolyl-4-hydroxylases
04/13/2011CN102015684A Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
04/13/2011CN102015683A Substituted indole derivatives
04/13/2011CN102015682A 3, 4 - substituted piperidine derivatives as renin inhibitors
04/13/2011CN102015681A Crystal form of phenylamino pyrimidine derivatives
04/13/2011CN102015680A New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
04/13/2011CN102015678A Fused pyridines active as inhibitors of c-Met
04/13/2011CN102015677A Pyrimidinone derivatives and methods of use thereof
04/13/2011CN102015675A Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin
04/13/2011CN102015674A Modulators of dopamine neurotransmission
04/13/2011CN102015673A Macrocyclic prodrug compounds useful as therapeutics
04/13/2011CN102015668A Piperazine derivatives and their use as leptin receptor modulators
04/13/2011CN102015667A Aminodihydrothiazine derivatives as BACE inhibitors for the treatment of alzheimer's disease
04/13/2011CN102015665A Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
04/13/2011CN102015664A Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
04/13/2011CN102015662A 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
04/13/2011CN102015660A 2-aminoquinazoline derivative
04/13/2011CN102015658A Benzimidazole derivatives
04/13/2011CN102015656A Phenylpropionic acid derivative and use thereof
04/13/2011CN102015655A Trisubstituted pyrazoles as acetylcholine receptor modulators
04/13/2011CN102015651A Compounds and compositions as TLR activity modulators
04/13/2011CN102015650A 2-aminoquinoline derivatives as 5-HT(5A) receptor antagonists
04/13/2011CN102015647A Process for production of compound having antagonistic activity on NPYY5 receptor, and useful crystal
04/13/2011CN102015645A Piperidine and pyrrolidine compounds
04/13/2011CN102015644A Hydroxyalkanyl amides as modulators of chemokine receptor activity
04/13/2011CN102015642A Novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof
04/13/2011CN102015641A Heterocyclic compound
04/13/2011CN102015640A Substituted 4-aminocyclohexane derivatives for the treatment of pain
04/13/2011CN102015639A Compounds for use in stabilizing p53 mutants
04/13/2011CN102015638A Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
04/13/2011CN102015637A Novel phenylpyrrole derivative
04/13/2011CN102015636A Azetidines and cyclobutanes as histamine H3 receptor antagonists
04/13/2011CN102015626A 4-trimethylammonio-butyrates as CPT2 inhibitors
04/13/2011CN102015610A Pharmaceutical gallium compositions and methods
04/13/2011CN102015607A 1,4-naphthoquinone derivatives and therapeutic use thereof
04/13/2011CN102015012A Local embolization via heating of thermosensitive polymers
04/13/2011CN102014961A Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
04/13/2011CN102014960A Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof
04/13/2011CN102014957A Auris formulations for treating otic diseases and conditions
04/13/2011CN102014932A Compositions and methods for inhibiting expression of Eg5 and VEGF genes
04/13/2011CN102014930A Compositions comprising ARNOX-inhibitors for the inhibition of reactive oxygen species
04/13/2011CN102014929A Enzymatic substrates for multiple detection systems
04/13/2011CN102014928A Methods of identifying genes involved in memory formation using small interfering rna (siRNA)
04/13/2011CN102014927A Boron-containing small molecules as anti-inflammatory agents
04/13/2011CN102014926A Methods and kits for the treatment of inflammatory bowel disorder conditions
04/13/2011CN102014925A Fulvestrant formulations
04/13/2011CN102014924A Treatment of meconium aspiration syndrome with estrogens
04/13/2011CN102014923A Pregesteron antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
04/13/2011CN102014922A Use of maslinic acid for the treatment of diseases and the symptoms thereof by means of COX-2 inhibition